Filing Flows › AbbVie (ABBV) › Q2 2026 › vs Q2 2025
AbbVie (ABBV) Q2 2026 vs Q2 2025 (year over year)
AbbVie's revenue rose $1.6B (+10%) from $15.4B in Q2 2025 to $17.0B in Q2 2026. Operating margin 37.9% against 31.7% (+6.1 pts).
AbbVie, Q2 2026: revenue $17.0B (+10% year over year), operating margin 37.9%, net earnings $3.6B, operating cash flow $3.4B. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 37.9% | 31.7% | +6.1 pts |
| Net margin | 21.3% | 6.1% | +15.2 pts |
| Free cash flow margin | 18.3% | 31.7% | -13.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $17.0B | $15.4B | $1.6B | +10% |
| Operating profit | $6.4B | $4.9B | $1.5B | +31% |
| Costs & expenses | $10.6B | $10.5B | $29.0M | +0.3% |
| Pre-tax earnings | $4.3B | $1.6B | $2.7B | +175% |
| Other expense, net | $2.2B | $3.3B | −$1.2B | -36% |
| Cost of revenue | $4.3B | $4.3B | −$55.0M | -1% |
| Research & development | $2.3B | $2.1B | $213M | +10% |
| SG&A | $3.6B | $3.3B | $379M | +12% |
| Other operating costs | $291M | $799M | −$508M | -64% |
| Net earnings | $3.6B | $941M | $2.7B | +284% |
| Income tax | $662M | $613M | $49.0M | +8% |
| Depreciation & amortization | $1.9B | $2.1B | −$192M | -9% |
| Share-based compensation | $166M | $179M | −$13.0M | -7% |
| Working capital & other | $2.2B | −$1.9B | $4.2B | — |
| Operating cash flow | $3.4B | $5.2B | −$1.7B | -33% |
| Free cash flow (OCF − capex) | $3.1B | $4.9B | −$1.8B | -36% |
| Capital expenditures | $322M | $269M | $53.0M | +20% |
Questions
How much did AbbVie's revenue grow year over year in Q2 2026?
AbbVie's revenue rose $1.6B (+10%) from $15.4B in Q2 2025 to $17.0B in Q2 2026. Operating margin 37.9% against 31.7% (+6.1 pts).